Active/Awarded Grants
- A Novel First-in-class Technology for Advanced Manufacturing of Complex Vaccine Formulations against Influenza and Emerging Infectious Diseases (OSP 202101088), NIH – FDA; Sep 2021-Aug 2024; USD 1,495,036; Principal Investigator (PI)
- 3D-printed Implantable Device for Long-acting Contraceptive Delivery (UCS-21-009), USAID; Dec 2021- Jun 2023; USD 224,926; PI
- Ultra-smart 3D printing platform for the fabrication of person specific pills (OSP Nbr 202000967 – 001); Sep 2020 – Aug 2023; USD 520,000; PI
- Continuous manufacturing of pharmaceuticals and 3D printable dosage forms; Industrial Strat. & Dev. Fund (OSP Nbr: 201901238 – 001); Sep 2019 – Aug 2022; USD 654,240; PI
- Novel hybrid anti-viral smart drug delivery systems (nParticl3D) to treat COVID-19 (OSP 202001672-001); Jun 2020- May 2021; USD 200,000; PI
- Innovative manufacturing platform for vitamin and Fe enriched novel food supplements; GoK-FB131K; Apr 2021 – Aug 2023; USD 366,000; International Consultant (Co-PI)
- Science and Technology Acquisition and Retention Program – “Pharmaceutical Processing and Additive Manufacturing”; Rising STARs Fund; May 2019 – Apr 2022; USD 300,000; Awardee
- Smart hybrid bandage for chronic wound management and healing, GBP 23,000; PI
- Biocompatible devices via 3D printing and 3D bioprinting; Sep 2017 – Aug 2021; Chinese Scholarship Council (CSC); GBP 225,000; Host supervisor – mentor
Non-Federal or Foundation Grants/Contracts
- Cardioprotective Drug Pilot Investigation (DRZ); Dell Children’s Foundation (OSP Nbr: 202101938 – 001), TX; $49,500; Sep 2021- Aug 2022; PI
- 3D printing and ramp-up of medical devices (OSP Nbr: 202101570 – 001); SS LLC, Texas; $70,000; Jul 2021 – May 2022; PI
Research Awards
- 3D Printed Medicines for Patient-Specific Treatment of COVID-19; Texas Global Faculty Research Seed Grant; 06/01/2021 – 31/03/2022; PI
- Stem cell drug delivery systems for SARS-CoV-2; Research Reboot Program 2021; 06/01/2022; PI
Pending Federal/Non-Federal Grants
- SMART: a first-in-class technology for on-demand manufacturing of mRNA vaccines, BARDA, $750K, (Feb 2023-Aug 2024); PI
- Continuous manufacturing of pharmaceuticals and 3D printable dosage forms (UTA19 -000602), Industry Fund; $1.5 million (Sep 2023 – Aug 2026); PI